XenoGesis and Juniper Pharma Services have extended their partnership in early drug development services by adding GastroPlus, PBPK modelling and simulation software.
Partnership
“We are delighted to be further strengthening our relationship with XenoGesis with their addition of GastroPlus,” explained Claire Madden-Smith, SVP at Juniper Pharma Services. “Our combined offering provides our clients unique access to development and DMPK expertise that is truly advancing programmes smartly and rapidly.”
Jointly, the companies are working together on a number of projects combining the Enabling Technologies Rapid Screen and GastroPlus. Through the expanded partnership, the companies anticipate to be able to offer a greater understanding of a compound’s potential exposure in both preclinical and clinical studies.
GastroPlus software simulates absorption, distribution, metabolism and elimination in humans and animals from a range of dose routes. As such, data integration within a virtual human or animal model is made possible. Additionally, in silico understanding can help make fast and informed development decisions.
“We continue to invest in the best technology and systems to support our clients and help them to achieve greater success in their drug discovery projects,” added Richard Weaver, managing director at XenoGesis. “We work closely with our partner at Juniper Pharma Services, to bring GastroPlus and their Enabling Technologies Rapid Screen together to offer a unique service to our joint clients.”
“For researchers in the life sciences sector, it is difficult to measure everything as a project winds its way through the R&D process. Data that is generated is often difficult to interpret, yet expected to inform speedy decisions that influence the drug development project. Making the wrong decision can be costly in terms of time and money,” stated Graham Trevitt, director of DMPK, Consultancy, Modelling & Simulation at XenoGesis. “GastroPlus gives our clients access to a gold standard tool that will help them understand the potential exposure of a compound in both pre-clinical and clinical studies. By integrating PK-PD data, this allows prediction of efficacious doses.”